What is the 13F Pro Quality Score for RAPP?

13F Pro ranks Rapport Therapeutics, Inc. (RAPP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RAPP's current score at https://13fpro.ai/research/RAPP (free sign-up required for the full ranking).

Which hedge funds own the most RAPP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RAPP include FMR, TRV GP V,, ARCH Venture Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RAPP as soon as new 13F filings post.

Where does 13F Pro source RAPP data?

All Rapport Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Rapport Therapeutics, Inc. files with the SEC under CIK 2012593. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RAPP in?

Rapport Therapeutics, Inc. (RAPP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RAPP research updated on 13F Pro?

RAPP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Rapport Therapeutics, Inc.(RAPP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 2012593 RAPP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RAPP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Rapport Therapeutics, Inc. (RAPP), a Healthcare sector company. RAPP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Rapport Therapeutics, Inc. reports quarterly revenue of $20.0M, net income of $-19.9M, free cash flow of $-13.1M. Top institutional holders of RAPP by reported 13-F value include FMR, TRV GP V,, ARCH Venture Management,, based on the most recent SEC filings. RAPP trades on the Nasdaq exchange and files with the SEC under CIK 2012593. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RAPP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rapport Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$20.0M

Net Income

Q1 2026

$-19.9M

Free Cash Flow

Q1 2026

$-13.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-42.4% YoY

$-111.5MFY 2025

FY23 $-34.8MFY24 $-78.3MFY25 $-111.5M

Operating Income

-50.6% YoY

$-125.1MFY 2025

FY23 $-36.2MFY24 $-83.1MFY25 $-125.1M

EPS (Diluted)

+24.3% YoY

$-2.86FY 2025

FY23 $-23.10FY24 $-3.78FY25 $-2.86

Total Assets

+62.7% YoY

$512.4MFY 2025

FY23 $155.4MFY24 $314.9MFY25 $512.4M

Op. Cash Flow

-34.9% YoY

$-87.5MFY 2025

FY23 $-27.2MFY24 $-64.8MFY25 $-87.5M

Metric	FY 2025	FY 2024	FY 2023
Net Income	$-111.5M -42.4%	$-78.3M -125.1%	$-34.8M
Operating Income	$-125.1M -50.6%	$-83.1M -129.6%	$-36.2M
EPS (Diluted)	$-2.86 +24.3%	$-3.78 +83.6%	$-23.10
Total Assets	$512.4M +62.7%	$314.9M +102.6%	$155.4M
Operating Cash Flow	$-87.5M -34.9%	$-64.8M -138.5%	$-27.2M

AI Insight: RAPP Financial Trends

First revenue recognition ($20M in Q1 2026) marks a potential inflection, but cumulative equity erosion of ~$73M since Q3 2025 capital raise signals ongoing cash burn pressure.

• Q1 2026 marks the first reported revenue of $20M, a meaningful milestone for this pre-commercial-stage biotech.

• Net loss narrowed sharply to $-20M in Q1 2026 from $-34M in Q4 2025, the best result in four quarters.

• Equity declined steadily from $337M in Q2 2024 to $264M by Q2 2025, before a capital raise boosted it to $512M in Q3 2025.

• Operating cash outflow improved to $-13M in Q1 2026 from $-25M in Q4 2025, the lowest burn in five quarters.

⚠ Equity has eroded from $512M to $472M in two quarters post-raise; sustained burn could require another dilutive capital event.

⚠ Operating losses widened consistently from $-22M in Q3 2024 to $-39M in Q4 2025 — Q1 2026 improvement must hold.

⚠ Revenue appeared only in Q1 2026; durability and trajectory of this revenue line remain unproven with a single data point.

AI Insight: RAPP Ratio Trends

Return metrics show meaningful improvement in Q1 2026, but deeply negative ROIC across all periods signals ongoing cash burn typical of a clinical-stage biotech.

• ROE improved from -40.6% in Q2 2025 to -16.9% in Q1 2026, the least negative reading in the observable period.

• ROIC recovered from a trough of -44.8% in Q2 2025 to -20.5% in Q1 2026, a 24pp improvement over three quarters.

• Operating margin of -121.1% and NPM of -99.3% in Q1 2026 confirm the company generates no revenue against heavy R&D spend.

⚠ ROE, ROA, and ROIC all deteriorated sharply from Q3 2024 through Q2 2025 before rebounding — sustainability of that recovery is unproven.

⚠ D/E data is absent throughout; inability to assess leverage leaves balance-sheet risk unquantified.

⚠ TTM ROIC of -25.9% versus Q1 2026 annualized -20.5% suggests recent-quarter improvement may partly reflect one-off timing effects.

Get alerted when RAPP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rapport Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RAPP

FMR LLC
$224.3M7,168,939 sh
TRV GP V, LLC
$223.3M7,135,233 sh
ARCH Venture Management, LLC
$116.7M3,728,738 sh
Capital International Investors
$96.9M3,097,973 sh
Cormorant Asset Management, LP
$92.5M2,957,521 sh
GOLDMAN SACHS GROUP INC
$92.1M2,942,251 sh
BlackRock, Inc.
$78.4M2,505,955 sh
Sofinnova Ventures Inc
$59.6M1,904,408 sh
JOHNSON & JOHNSON
$55.8M1,784,517 sh
Polar Capital Holdings Plc
$51.4M1,642,461 sh

Fund	Value	Shares
FMR LLC	$224.3M	7,168,939
TRV GP V, LLC	$223.3M	7,135,233
ARCH Venture Management, LLC	$116.7M	3,728,738
Capital International Investors	$96.9M	3,097,973
Cormorant Asset Management, LP	$92.5M	2,957,521
GOLDMAN SACHS GROUP INC	$92.1M	2,942,251
BlackRock, Inc.	$78.4M	2,505,955
Sofinnova Ventures Inc	$59.6M	1,904,408
JOHNSON & JOHNSON	$55.8M	1,784,517
Polar Capital Holdings Plc	$51.4M	1,642,461

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RAPP on your watchlist

Track score changes the day Rapport Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RAPP a good stock to buy?

13F Pro's AI-powered analysis of Rapport Therapeutics, Inc. (RAPP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RAPP are available on the RAPP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RAPP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RAPP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rapport Therapeutics, Inc.'s investment landscape.